vcap cell line Search Results


vcap  (ATCC)
99
ATCC vcap
Vcap, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vcap/product/ATCC
Average 99 stars, based on 1 article reviews
vcap - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
ducap prostate cancer cells  (Radboud University)
90
Radboud University ducap prostate cancer cells
a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; <t>DuCaP,</t> N = 3, N represents number of biologically independent <t>experiments)</t> <t>prostate</t> cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.
Ducap Prostate Cancer Cells, supplied by Radboud University, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ducap prostate cancer cells/product/Radboud University
Average 90 stars, based on 1 article reviews
ducap prostate cancer cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human pc cell line vcap  (European Collection of Authenticated Cell Cultures)
90
European Collection of Authenticated Cell Cultures human pc cell line vcap
a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; <t>DuCaP,</t> N = 3, N represents number of biologically independent <t>experiments)</t> <t>prostate</t> cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.
Human Pc Cell Line Vcap, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pc cell line vcap/product/European Collection of Authenticated Cell Cultures
Average 90 stars, based on 1 article reviews
human pc cell line vcap - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human prostate cancer cell line vcap  (Dawley Inc)
90
Dawley Inc human prostate cancer cell line vcap
a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; <t>DuCaP,</t> N = 3, N represents number of biologically independent <t>experiments)</t> <t>prostate</t> cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.
Human Prostate Cancer Cell Line Vcap, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human prostate cancer cell line vcap/product/Dawley Inc
Average 90 stars, based on 1 article reviews
human prostate cancer cell line vcap - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
vcap cell line  (Inserm Transfert)
90
Inserm Transfert vcap cell line
a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; <t>DuCaP,</t> N = 3, N represents number of biologically independent <t>experiments)</t> <t>prostate</t> cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.
Vcap Cell Line, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vcap cell line/product/Inserm Transfert
Average 90 stars, based on 1 article reviews
vcap cell line - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human prostate cancer cell lines vcap  (Korean Cell Line Bank)
90
Korean Cell Line Bank human prostate cancer cell lines vcap
a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; <t>DuCaP,</t> N = 3, N represents number of biologically independent <t>experiments)</t> <t>prostate</t> cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.
Human Prostate Cancer Cell Lines Vcap, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human prostate cancer cell lines vcap/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
human prostate cancer cell lines vcap - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cell line vcap  (iCell Bioscience Inc)
90
iCell Bioscience Inc cell line vcap

Cell Line Vcap, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell line vcap/product/iCell Bioscience Inc
Average 90 stars, based on 1 article reviews
cell line vcap - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human vertebral-cancer of the prostate (vcap) cell line  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare human vertebral-cancer of the prostate (vcap) cell line

Human Vertebral Cancer Of The Prostate (Vcap) Cell Line, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vertebral-cancer of the prostate (vcap) cell line/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
human vertebral-cancer of the prostate (vcap) cell line - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; DuCaP, N = 3, N represents number of biologically independent experiments) prostate cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation

doi: 10.1038/s41467-020-15237-5

Figure Lengend Snippet: a Relative GM-OXPHOS respiratory capacity with glutamate&malate (GM P /NS E ) in benign (blue) or malignant (red) samples carrying either no or only synonymous HPs (−) ( N BE = 36 and N CA = 23) versus samples carrying non-synonymous HPs (+) ( N BE = 14 and N CA = 27) in the coding regions of the mt-genome. Values present mean ± SD. Differences in mean values were tested for significance using Wilcoxon rank-sum test. b Comparison of relative GM-OXPHOS capacity in samples without mutations (−) ( N BE = 38 and N CA = 37) versus samples with mutations (+) ( N BE = 12 and N CA = 13) within the non-coding (control) region of the mt-genome. Values represent mean ± SD. c Impact of location of non-synonymous HPs on relative GM-OXPHOS capacities. Tumor tissue samples were categorized according to no HPs (−) (orange; N = 24), and HPs located in genes encoding proteins of CIII–CV (CO, ATP, CYB; green; N = 10) or in genes encoding proteins of CI (ND1–ND5; blue; N = 20). d – e Relative GM-OXPHOS (GM P /NS E , d ) and relative S-ET (S E /NS E , e ) respiratory capacities in malignant tissue samples harboring non-synonymous HPs in CI-coding mt-genes. Tumors were grouped into samples carrying no non-synonymous HPs ((−); N = 23), samples with variant levels of 30–60% (30–60%; N = 6) and samples with variant levels >60% (>60%; N = 4). Differences in mean values were tested for significance using one-way ANOVA followed by Tukey’s HSD test. f N-pathway (blue) and S-pathway (orange) respiratory capacities in malignant samples harboring high-level (>60%) non-synonymous HPs in either CIV-coding genes ( N = 4) or CI-coding genes ( N = 4). Differences of in mean values were tested for significance using Wilcoxon rank-sum test. Values presented in c-f represent mean values and individual data points. g S-pathway OXPHOS capacity upregulation by partial inhibition of N-pathway oxidative flux in benign (RWPE1, N = 3; EP156T, N = 3) and malignant (PC3, N = 6; LNCaP, N = 4; DuCaP, N = 3, N represents number of biologically independent experiments) prostate cell lines. Relative S-pathway OXPHOS capacity (normalized to total respiratory capacity, NS E ) with different degrees of N-pathway inhibition is shown for the five cell lines. Values represent mean ± SD. Source data are provided as a Source Data file.

Article Snippet: DuCaP prostate cancer cells were a gift from Dr. Schalken (Radboud University, Nijmegen, The Netherlands).

Techniques: Comparison, Control, Variant Assay, Inhibition

Journal: eLife

Article Title: circFL-seq reveals full-length circular RNAs with rolling circular reverse transcription and nanopore sequencing

doi: 10.7554/eLife.69457

Figure Lengend Snippet:

Article Snippet: Cell line ( H. sapiens ) , VCaP , iCell Bioscience , RRID: CVCL_2235 , .

Techniques: